Comparative Evaluation of Artificial Intelligence and Endoscopists´ Accuracy in Endoscopic Ultrasound for Identifying Normal Anatomical Structures: A Multi-institutional, Cross-sectional Study

Endoscopic ultrasound (EUS) visual impression is operator-dependant and can hinder diagnostic accuracy, especially in less experienced endoscopists. The implementation of artificial intelligence can potentially mitigate operator dependency and interpretation variability, helping or improving the overall accuracy.
The investigators therefore aim to compare diagnostic accuracy between artificial intelligence (AI)-based model and the endoscopists when identifying normal anatomical structures in EUS-procedures.

开始日期2023-05-01

申办/合作机构

Universitair Ziekenhuis Brussel

[+5]

NCT04854486

/ Withdrawn临床3期IIT

Impact of GSE and Xylitol (Xlear) in Symptoms and Time to PCR Negativisation of Patients With Acute COVID-19 Infection

This clinical trial aims to ascertain the impact of GSE and Xylitol (XLEAR) in decreasing the time of negativisation in PCR testing in patients with COVID-19.

开始日期2021-12-16

申办/合作机构

Larkin Community Hospital, Inc.

NCT04610801

/ Withdrawn临床3期IIT

A Randomized Placebo Control Trial to Evaluate the Efficacy of Xylitol Nasal Spray vs. Placebo for Acute COVID-19 Infection

The purpose of this study is to assess the efficacy of Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray as an adjunct treatment of COVID-19.

开始日期2021-12-08

申办/合作机构

Larkin Community Hospital, Inc.

[+2]

100 项与 Larkin Community Hospital, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Larkin Community Hospital, Inc. 相关的专利（医药）

登录后查看更多信息

528

项与 Larkin Community Hospital, Inc. 相关的文献（医药）

2025-12-31·Case Reports in Plastic Surgery and Hand Surgery

Beyond excision: modern plastic surgery techniques for hidradenitis suppurativa reconstruction

Article

作者: Salgado, Christopher J. ; Sanchez Eligio, Ruben

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder characterized by recurrent abscesses, sinus tract formation and extensive scarring. In severe cases, surgical excision and complex reconstruction are often required. This case report aims to highlight the role of modern plastic surgical techniques, including regenerative technologies, in managing severe HS. A 37-year-old Hispanic male with a 17-year history of HS presented with extensive lesions involving the buttocks, groin, genitalia, thighs and perianal region. He underwent staged wide excisions totaling over 2,400 cm². Reconstruction included split-thickness skin grafts (STSG), NovoSorb^® BTM (Biodegradable Temporizing Matrix) and RECELL^® autologous skin cell suspension. Postoperative recovery was marked by successful graft take, wound healing and return to normal function, including physical activity and sexual function, by postoperative day 69. This case underscores both the complexity of managing stage III HS and the evolving role of regenerative technologies in improving outcomes. While wide local excision remains the cornerstone of treatment for extensive disease, adjunctive use of BTM and RECELL enhances dermal regeneration, reduces donor-site morbidity and optimizes aesthetic and functional results. These innovations reflect a shift in reconstructive strategy, emphasizing a more tailored, patient-centered approach. The integration of regenerative modalities such as Biodegradable Temporizing Matrix (BTM) and RECELL autologous cell suspension technology into contemporary plastic surgical reconstruction offers significant benefits in treating severe hidradenitis suppurativa. By complementing traditional excisional techniques, these technologies contribute to improved healing, minimized morbidity and restored function, aligning with the goals of modern, multidisciplinary HS management.

2025-12-01·JOURNAL OF INVESTIGATIVE DERMATOLOGY

Immune Activation and Glycolytic Responses to Cutibacterium acnes Cell Wall Polysaccharides

Article

作者: Nelson, Amanda M ; Deng, Min ; Agak, George W ; Evron, Evyatar ; Qin, Min ; Tran, Patrick Thanh ; Kim, Jenny

Carbohydrates are key components of many microbial cell walls and play a versatile role in immune recognition. In this study, we analyzed the carbohydrate cell wall composition of Cutibacterium acnes strains associated with healthy skin (denoted as C_H) and acne-prone skin (denoted as C_A) to understand their influence on host immune responses in acne. We identified glucose, mannose, and galactose as the primary monosaccharides, with minor amounts of fucose, N-acetylgalactosamine, and N-acetylglucosamine. Linkage analysis revealed structural variations between C_H and C_A strains: C_H strains showed a balanced and diverse polysaccharide structure, whereas C_A strains displayed a more rigid structure with 1→4 and branched 1→6 linkages, potentially contributing to inflammatory properties. Immunostimulatory assays revealed that C acnes carbohydrates induced IL-6 and IL-17 but not IL-1β, highlighting the role of carbohydrate structures in influencing cytokine responses. Treatment with sodium meta-periodate impaired this immunostimulatory activity, indicating that carbohydrate integrity is crucial for immune activation. In addition, analysis of single-cell RNA-sequencing data from acne lesions revealed elevated glycolytic activity in acne lesions in comparison with that in nonlesional skin, suggesting a Warburg-like effect that promotes inflammation. Our findings highlight the role of C acnes polysaccharides in immune modulation and inflammation, suggesting their potential as therapeutic targets for acne treatment.

2025-12-01·MAYO CLINIC PROCEEDINGS

Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis

Review

作者: Ang, Song Peng ; Reiner, Zeljko ; Banach, Maciej ; Toth, Peter P ; Gaita, Dan ; Amarenco, Pierre ; Sawhney, Aanchal ; Jaiswal, Vikash ; Lavie, Carl J ; Pećin, Ivan ; Deb, Novonil ; Penson, Peter E

OBJECTIVE:

To evaluate the efficacy of combination lipid-lowering therapy (LLT) compared with statin monotherapy for low-density lipoprotein cholesterol (LDL-C) reduction, associated adverse events, and outcomes.

METHODS:

A systematic literature search was conducted using PubMed, Embase, and ClinicalTrials.gov to identify relevant articles published from inception until the end of June 2024. The outcomes were assessed using pooled odds ratios (ORs) for categorical data and mean difference for continuous data, with corresponding 95% CIs.

RESULTS:

A total of 14 studies (11 randomized controlled trials and 3 cohort studies) with 108,373 very high-risk patients were included in the final analysis. The mean age of the patients in the combination LLT group and the statin monotherapy group was 67.31 and 67.89 years, respectively. Pooled analysis revealed that combination LLT significantly more effectively reduced the LDL-C level from baseline (mean difference, -12.96 mg/dL; 95% CI, -17.27 to -8.65; P<.001) and significantly reduced all-cause mortality (OR, 0.81; 95% CI, 0.67 to 0.97; P=.02), major adverse cardiovascular events (OR, 0.82; 95% CI, 0.69 to 0.97; P=.02), and stroke incidence (OR, 0.83; 95% CI, 0.75 to 0.91; P<.001), with an insignificant effect on cardiovascular mortality (OR, 0.86; 95% CI, 0.65 to 1.12; P=.26) when compared with statin monotherapy. The risk of adverse events and the therapy discontinuation rate were comparable between groups.

CONCLUSION:

Combination LLT was associated with an overall greater reduction in LDL-C, the same risk of adverse effects, and significantly lower risk of all-cause mortality, major adverse cardiovascular events, and stroke compared with statin monotherapy. Forthcoming guidelines should consider the lipid-lowering combination therapy as early as possible, preferably up-front, for more effective LDL-C goal achievement and significant reduction of cardiovascular disease outcomes and mortality in high- and very high-risk patients.

项与 Larkin Community Hospital, Inc. 相关的新闻（医药）

2025-06-17

·PRNewswire

Larkin Hospital Earns Comprehensive Stroke Center Designation

MIAMI, June 17, 2025 /PRNewswire/ -- Larkin Hospital is proud to announce that it has officially earned the prestigious Comprehensive Stroke Center designation, further solidifying its commitment to providing the highest standard of care for patients experiencing strokes. This distinction recognizes Larkin Hospital's exceptional capabilities in stroke treatment, advanced technology, and specialized care teams that are essential in the rapid diagnosis, management, and recovery of stroke patients. The Comprehensive Stroke Center designation is granted by ACHC, a national accrediting body known for setting rigorous standards in healthcare. This achievement highlights Larkin Hospital's ability to provide life-saving interventions, such as thrombectomy and thrombolytic therapy, and offer the specialized services necessary to treat the most complex and severe stroke cases. "We are incredibly proud of this accomplishment and the dedication of our entire medical team," said Dr. Wilson Cueva, Director of the Comprehensive Stroke Center at Larkin Community Hospital Palm Springs, "Being recognized as a Comprehensive Stroke Center reflects our commitment to providing state-of-the-art care for stroke patients and ensuring the best possible outcomes through a collaborative, multidisciplinary approach." Stroke remains one of the leading causes of death and disability in the United States, and timely access to expert care is crucial. Larkin Hospital's Comprehensive Stroke Center designation ensures that patients receive rapid access to expert neurologists, emergency response teams, advanced imaging capabilities, and ongoing rehabilitation services. The hospital's stroke care team includes physicians, nurses, therapists, and other specialists who work together to provide personalized care tailored to each patient's unique needs. "We are grateful for the trust that our community places in us and for the continued support of our patients and families," added Yoely Hernandez, CEO of Larkin Community Hospital Palm Springs Campus, "This achievement is a reflection of our ongoing commitment to improving the health and well-being of those we serve." About Larkin Health System At Larkin Health System, we have been serving the healthcare needs of South Miami, Hialeah, and the surrounding communities for over 60 years. We take pride in the continuing tradition of caring. We remain dedicated to providing excellent medical care with the personal touch and convenience that only a community hospital offers. We hope you can find health, comfort, and peace of mind due to your stay with us. At our hospital, we provide comprehensive healthcare to individuals using the biopsychosocial model of patient care, focusing on the family and the community. The Larkin medical staff is a faithful advocate of the genuine concept of optimal health: "A state of vitality to maintain enjoyment and satisfaction with life and not just the absence of disease." At Larkin Health System, we consider you, our customer, a valuable partner in our healthcare team. Our dedicated team of healthcare professionals is committed to providing high-quality service and making our patients stay as comfortable and pleasant as possible. Media: Patty Vila C: 305-498-9660 SOURCE Larkin Health System WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-04-22

·PRNewswire

NEW HOPE FOR TREMOR PATIENTS: FOCUSED ULTRASOUND NOW AVAILABLE IN MIAMI

No Surgery. No Scalpels. No Recovery Time. Tremors Gone in Minutes. MIAMI, April 22, 2025 /PRNewswire/ -- For millions living with Essential Tremor (ET), simple tasks like eating, writing, or holding a drink can feel impossible. Now, the Miami Neuroscience Center at Larkin is offering a revolutionary solution: Focused Ultrasound — a non-invasive, FDA-approved treatment delivering immediate relief without surgery or recovery time. Led by internationally renowned neurosurgeon Dr. Aizik Wolf, this state-of-the-art procedure is changing lives in real time. "We're seeing patients walk out of treatment tremor-free within hours," said Dr. Wolf, Medical Director at Miami Neuroscience Center. "The transformation is instant and life-changing." Why This Matters Essential Tremor affects over 10 million Americans. Until now, treatment options included invasive brain surgery or lifelong medications. Focused Ultrasound is a game-changer: No scalpels, cuts, or anesthesia FDA Approved MRI-guided precision Outpatient procedure — patients go home with results the same day Covered by Medicare and most major insurance plans This cutting-edge technology uses targeted sound waves to treat the area of the brain responsible for tremors — with no incisions or implants required. Real People. Real Results. "I couldn't hold a cup of coffee without spilling. After the procedure, I signed my name for the first time in 15 years." — Patient testimonial, Miami Neuroscience Center Watch the Transformation Spanish Video Version Before & After View Media Access Interviews available with: Dr. Aizik Wolf Dr. Jose Valerio Real patients with before-and-after success stories High-res images and video upon request Schedule a Consultation or Learn More: Call: (786) 871-6806 Email: [email protected] About Miami Neuroscience Center at Larkin Part of Larkin Health System, the Miami Neuroscience Center is a state-of-the-art facility offering advanced, patient-focused care for neurological conditions including brain tumors, AVMs, herniated discs, migraines, trigeminal neuralgia, and more. Treatments include Focused Ultrasound , Gamma Knife®, Zap-X®, and Airo® technology. Learn more: CONTACT: Frances Rodriguez | Marketing Director | [email protected] SOURCE Miami Neuroscience Center at Larkin WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-07-16

·PRNewswire

Florida Cancer Specialists & Research Institute Welcomes Hematologist & Medical Oncologist Francis Matuszak, DO to Ocala Offices

FORT MYERS, Fla., July 16, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that board-certified hematologist and medical oncologist Francis Matuszak, DO has joined the statewide practice. He is providing care to patients at the FCS Ocala Cancer Center, 4945 SW 49th Place, Ocala, FL 34474 and our FCS Ocala office, 1630 SE 18th St. Ste 602, Ocala FL 34471. Continue Reading Florida Cancer Specialists & Research Institute welcomes Francis Matuszak, DO to its Ocala office locations. Dr. Matuszak will be providing care to patients at the Ocala Cancer Center and Ocala office. Nathan H. Walcker, FCS chief executive officer, said, "We are delighted to welcome Dr. Matuszak to our team of top cancer experts in Marion County, where FCS is proud to provide a comprehensive range of services and the most advanced treatments that enable patients to achieve the best possible outcomes." Dr. Matuszak received his medical degree from Lake Erie College of Osteopathic Medicine in Bradenton, Florida. He completed internal medicine residency training and a fellowship in hematology and oncology at Larkin Community Hospital in Miami and was named chief resident and chief fellow. He has specialized training as an HIV specialist from the American Association of HIV Medicine. FCS President & Managing Physician Lucio Gordan, MD said, "Dr. Matuszak joins us with solid credentials and a commitment to supporting patients and their families through every step of their treatment journey." To learn more about Dr. Matuszak, click here. About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com) Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. The majority of new cancer drugs recently approved for use in the U.S. were studied in clinical trials with FCS participation.* Recognized for our research, FCS is a recipient of the national Clinical Trials Participation Award presented by the American Society of Clinical Oncology (ASCO). FCS physicians, trained in prestigious medical schools and research institutes, are consistently ranked nationally as Top Doctors by U.S. News & World Report. Celebrating its 40th year in 2024, FCS has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies genomic-based treatment and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff. *Prior to approval SOURCE Florida Cancer Specialists & Research Institute

高管变更免疫疗法ASCO会议

100 项与 Larkin Community Hospital, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Larkin Community Hospital, Inc. 相关的转化医学

登录后查看更多信息